Towards effective adjuvant treatment for urothelial cancer

Arlene O. Siefker-Radtke; Jianjun Gao

doi:10.1016/S1470-2045(14)71187-8

Towards effective adjuvant treatment for urothelial cancer

Arlene O. Siefker-Radtke, Jianjun Gao

Genitourinary Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	9-10
Number of pages	2
Journal	The lancet oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(14)71187-8
State	Published - 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(14)71187-8

Cite this

@article{1702056d5f2b413b95857f4e635f3b44,

title = "Towards effective adjuvant treatment for urothelial cancer",

author = "Siefker-Radtke, {Arlene O.} and Jianjun Gao",

note = "Funding Information: AOS-R has received grants from the US National Institutes of Health, Genentech, Michael and Sherry Sutton Fund for Urothelial Cancer, Dendreon, Bristol-Myers Squibb, and Millenium, and has received other financial support from Dendreon, Bristol-Myers Squibb, Janssen, Celgene, Threshold, Merck, and the US National Comprehensive Cancer Network. AOS-R has a patent pending for methods of characterising and treating molecular subsets of muscle-invasive bladder cancer. JJG declares no competing interests. ",

year = "2015",

doi = "10.1016/S1470-2045(14)71187-8",

language = "English (US)",

volume = "16",

pages = "9--10",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Towards effective adjuvant treatment for urothelial cancer

AU - Siefker-Radtke, Arlene O.

AU - Gao, Jianjun

N1 - Funding Information: AOS-R has received grants from the US National Institutes of Health, Genentech, Michael and Sherry Sutton Fund for Urothelial Cancer, Dendreon, Bristol-Myers Squibb, and Millenium, and has received other financial support from Dendreon, Bristol-Myers Squibb, Janssen, Celgene, Threshold, Merck, and the US National Comprehensive Cancer Network. AOS-R has a patent pending for methods of characterising and treating molecular subsets of muscle-invasive bladder cancer. JJG declares no competing interests.

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84926112596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926112596&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)71187-8

DO - 10.1016/S1470-2045(14)71187-8

M3 - Comment/debate

C2 - 25498220

AN - SCOPUS:84926112596

SN - 1470-2045

VL - 16

SP - 9

EP - 10

JO - The lancet oncology

JF - The lancet oncology

IS - 1

ER -

Towards effective adjuvant treatment for urothelial cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this